Featured
GSK enters agreement to acquire Aiolos Bio
AIO-001 has potential to expand GSK’s respiratory biologics portfolio to reach a broader portion of asthma patients
Pfizer and Astellas’ XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies received an approval by the U.S. Food and Drug Administration (FDA) of a supplemental New Drug Application for XTANDI
Lunit Secures $150 Million in Capital Increase
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the successful completion of a significant paid-in capital increase of $150 million.
Astellas to Acquire Propella Therapeutics
Astellas, through a U.S. subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas will acquire Propella.
Chinese Biopharma Firm WuXi XDC Climbs 36% on Debut in Hong Kong
A Chinese maker of drugs used in cancer treatments surged in Hong Kong after an initial public offering priced at the top of a marketed range, a rare case of strong demand for a listing in the financial hub of the year.
Flagship expands into Asia-Pacific with new Singapore hub
Biotechnology company creator Flagship Pioneering is expanding its global footprint, announcing Tuesday the establishment of a regional hub in Singapore.
Hostility toward the U.S. in China has dropped sharply, new poll shows
Attitudes in China have become friendlier to the U.S. this year, according to a new survey from Morning Consult. One factor could be the slowdown in China's economy.
Japan to scrap rule requiring testing of new drugs on Japanese
apan will ease regulations on clinical trials for new drugs developed overseas, Nikkei has learned, scrapping the rule that in principle drugs' safety must be tested on Japanese before they can be launched in the domestic market.
